Skip to content

We are currently experiencing some technical difficulties which may result in you experiencing longer than usual wait times on our telephone and chat channels. We apologise for the inconvenience but ask you to hold once in the queue as we will get to your call and resolve your query.

 

Rare disease launch insights report

Planning to launch a rare disease therapy in Europe?

Start here.

Our Rare Disease Launch Insights Report brings together insights from more than 30 years of Sciensus experience helping biopharma companies navigate the challenges of launching rare and orphan therapies across Europe.

Discover how to:

  • Navigate Europe’s complex regulatory and reimbursement landscape
  • Use Early Access Programmes as a bridge to payer and patient engagement
  • Manage the operational and supply chain demands unique to rare therapies
  • Leverage real-world data to demonstrate value and support HTA submissions
  • Strengthen adherence and patient outcomes through effective PSPs

Download your free copy and learn how to bring your rare therapy to European patients faster. 

Sciensus

About Sciensus

Sciensus is the UK’s leading provider of complex clinical care at home. For over 30 years, we have partnered with the NHS to deliver specialist medicines, clinical nursing and patient support to people living with cancer, rare diseases and complex long-term conditions – supporting more than 300,000 patients a year across 180+ NHS trusts.

Beyond the UK, Sciensus helps pharmaceutical and biotech companies reach patients across Europe, managing the regulatory, logistics and patient support complexity of launching medicines in multiple markets.

Learn more